UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| Date of Report (Date of Earliest Event Reported): | November 7, 2013 |
Endocyte,
Inc.
__________________________________________
(Exact name of registrant as specified in its charter)
| Delaware | 001-35050 | 35-1969-140 |
| _____________________ (State or other jurisdiction |
_____________ (Commission |
______________ (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
|
3000 Kent Avenue, Suite A1-100, West Lafayette, Indiana |
47906 | |
| _________________________________ (Address of principal executive offices) |
___________ (Zip Code) |
| Registrant’s telephone number, including area code: | 765-463-7175 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Top of the Form
| ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS |
On November 7, 2013, the Board of Directors (the “Board”) of Endocyte, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee, elected Colin Goddard, Ph.D., to the Board, with a term to expire at the Company’s 2014 annual meeting of stockholders. The appointment fills a directorship position on the Board created by the retirement of Douglas Bailey. Dr. Goddard has been appointed to the Compensation Committee, replacing Fred Middleton as a member of the Compensation Committee. There are no arrangements or understandings between Dr. Goddard and any other persons pursuant to which Dr. Goddard was selected as a director of the Company.
As a non-employee director, Dr. Goddard will participate in the non-employee director compensation arrangements described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 19, 2013.
A copy of the Company’s press release announcing the appointment of Dr. Goddard to the Board is attached hereto as Exhibit 99.1, and the information set forth therein is incorporated herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
| Exhibit No. | Description | |||
| 99.1 | Press release dated November 7, 2013 | |||
Top of the Form
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Endocyte, Inc. | ||||
| November 7, 2013 | By: | /s/ Beth A. Taylor | ||
| Name: Beth A. Taylor | ||||
| Title: Corporate Controller | ||||
Top of the Form
Exhibit Index
| Exhibit No. | Description | |
| 99.1 | Press release dated November 7, 2013 |
Exhibit 99.1
Contacts:
Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200
Martina Schwarzkopf, Ph.D., Russo Partners, (212) 845-4292
Tony Russo, Ph. D., Russo Partners, (212) 845 4251
NEWS RELEASE
Colin Goddard, Ph.D., Joins the Endocyte Board of Directors
West Lafayette, Ind., Nov. 7, 2013 – Endocyte, Inc. (NASDAQ Global Market: ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Colin Goddard, Ph.D. has joined Endocyte’s board of directors.
Dr. Goddard is chief executive officer (CEO) and chairman of Coferon, Inc., a privately held biotechnology company, and director of the biotech companies Agendia and PanOptica as well as an advisor to venture capital firms. Prior to joining Coferon, Dr. Goddard was CEO of OSI Pharmaceuticals, leading the company through its transition from a technology platform to profitable biopharmaceutical company, until its acquisition by Astellas Pharma for $4 billion. Dr. Goddard joined OSI as a scientist in 1989, and served as president and chief operating officer (COO) before assuming the CEO role in 1998.
“Dr. Goddard will provide valuable insight and perspective at this dynamic time in Endocyte’s growth and development,” said Ron Ellis, president and CEO of Endocyte. “Dr. Goddard’s decades of leadership experience and instrumental role in the clinical development and launch of OSI’s flagship product, Tarceva®, will be valuable for Endocyte as we advance our development programs of SMDCs and companion imaging agents into multiple near-term clinical trial launches and continue the development of our lead SMDC, vintafolide, and its companion imaging agent, etarfolatide.”
Dr. Goddard received a doctorate in cancer pharmacology from the Aston University in Birmingham, United Kingdom, and a bachelor’s degree in biochemistry from the University of York, in York, United Kingdom. Dr. Goddard has received several awards and honorary degrees and authored numerous peer-reviewed publications.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.